India, Aug. 17 -- Nasus Pharma Ltd. (NSRX), a clinical-stage pharmaceutical company developing innovative intranasal therapies, reported financial results for the first half of 2026 and provided updates on its clinical pipeline.
The company has completed a Phase 2 study of NS002, its intranasal epinephrine powder for anaphylaxis, and is preparing to advance the candidate into a pivotal trial.
The company is also preparing NS003, an intranasal ondansetron formulation for chemotherapy-induced and post-operative nausea and vomiting, for first-in-human clinical testing.
H1 2026 Financial Highlights:
For the six months ended June 30, 2026, Nasus reported a net loss of $5.9 million, or $0.54 per share, compared with a net loss of $1.3 million...